Dow Down 0.17% Nasdaq Down 0.28%

ArQule Inc. (ARQL)

-NasdaqGM
1.12 Sep 30, 4:00PM EDT
Prev Close:1.12
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:3.06
Beta:1.25
Earnings Date:Nov 5 - Nov 10 (Est.)
Day's Range:N/A - N/A
52wk Range:1.08 - 2.92
Volume:0
Avg Vol (3m):229,762
Market Cap:70.31M
P/E (ttm):N/A
EPS (ttm):-0.41
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Headlines

» More Headlines for ARQL

Comparison

Symbol% ChgMkt Cap
ARQL 0.00%70.31M
ARRY470.60M

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):6.17
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-14) :-0.46
Quarterly EPS Est (Sep-14) :-0.13
Mean Recommendation*:2.6
PEG Ratio (5 yr expected):-0.51

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical... View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback